Trials / Completed
CompletedNCT05286281
A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803
A PHASE 1, OPEN-LABEL, SINGLE-PERIOD, NON-RANDOMIZED STUDY TO EVALUATE THE PHARMACOKINETICS, EXCRETION, MASS BALANCE AND METABOLISM OF [14C]PF-07265803 ADMINISTERED ORALLY TO HEALTHY ADULT MALE PARTICIPANTS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetics, excretion, mass balance and metabolism of PF-07265803 (formerly known as ARRY-371797) in approximately 6 healthy adult male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-07265803 | PF-07265803 is a p38 inhibitor formulated for oral delivery. |
Timeline
- Start date
- 2022-03-31
- Primary completion
- 2022-05-26
- Completion
- 2022-05-26
- First posted
- 2022-03-18
- Last updated
- 2024-03-29
- Results posted
- 2024-03-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05286281. Inclusion in this directory is not an endorsement.